-       Report 
- September 2025
-  313 Pages 
- Global 
   From       €4428EUR$4,950USD£3,895GBP 
          -       Report 
- May 2025
-  226 Pages 
- Global 
   From       €2236EUR$2,500USD£1,967GBP 
          -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
            -       Clinical Trials 
- November 2024
-  450 Pages 
- Global 
   From       €3578EUR$4,000USD£3,147GBP 
      €4472EUR$5,000USD£3,934GBP 
           -       Report 
- June 2022
-  242 Pages 
- Global 
   From       €3220EUR$3,600USD£2,832GBP 
                -       Book 
- May 2018
- North America 
                        
      Bone metastasis is a common complication of cancer, where cancer cells spread to the bones from other parts of the body. It is most commonly seen in cancers such as breast, prostate, lung, and kidney. Symptoms of bone metastasis include pain, fractures, and decreased mobility. Treatment options include radiation therapy, chemotherapy, and targeted therapies. Surgery may also be used to remove the cancer cells from the bone.
The bone metastasis market is a subset of the oncology market, and is    expected to grow due to the increasing prevalence of cancer and the development of new treatments. The market is driven by factors such as the increasing geriatric population, rising healthcare expenditure, and the availability of advanced treatments.
Some companies in the bone metastasis market include Novartis, Amgen, Merck, Pfizer, and Eli Lilly. Show Less   Read more